Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines.
Denis S FedorinovVladimir K LyadovDmitriy A SychevPublished in: Drug metabolism and personalized therapy (2021)
This review aimed to summarize the pharmacogenetic studies of the most commonly used drugs in the chemotherapy of gastrointestinal (GI) tumors: oxaliplatin, irinotecan, and fluoropyrimidines. So far, it has not been possible to develop an effective genotype-based approach for oxaliplatin. More and more evidence is emerging in favor of the fact that the choice of a dose of fluorouracil based on pharmacogenetic testing according to DPYD*2A , can be not only effective but also cost-effective. Additional, well-planned trials of the UGT1A1 genotype-based approach to irinotecan therapy are predicted to reduce adverse drug events in people with the UGT1A1*28/*28 genotypes and improve treatment efficacy in the rest of the patients, which might be cost-effective.
Keyphrases
- adverse drug
- end stage renal disease
- newly diagnosed
- ejection fraction
- locally advanced
- prognostic factors
- emergency department
- stem cells
- patient reported outcomes
- squamous cell carcinoma
- decision making
- chemotherapy induced
- electronic health record
- bone marrow
- radiation therapy
- mesenchymal stem cells
- replacement therapy
- combination therapy
- patient reported